

UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody

- UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases
- Deal strengthens UCB's leadership in immunology and expands capabilities in next-generation biologics

Brussels (Belgium) and Hong Kong, 3 March 2026 – 23:00 CET – UCB, a global biopharmaceutical company, and Antengene Corporation Limited (Antengene), an innovative, commercial-stage global biotech company today announced that they have entered into an agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201 and access to its associated manufacturing technology in relation to ATG-201.

T-cell engager's (TCE's) targeting B cell depletion, are a class of therapeutic agents designed to selectively target and eliminate B cells, which play a role in various diseases, including autoimmune disorders and certain haematological cancers. Specifically, ATG-201 is a CD19 targeting bispecific TCE designed to eliminate CD19-expressing B cells. This bispecific interaction with T and B cells through CD3 and CD19 has demonstrated potential in treating B cell-driven diseases by leveraging the body's own immune system for precise and potent action.

Antengene plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026. Antengene will complete first-in-human phase 1 studies in these two jurisdictions and thereafter transfer further ATG-201 clinical and other development to UCB.

"UCB is pleased to partner with Antengene on ATG-201, a novel B cell-depleting immune cell engager designed to provide a targeted, durable, and scalable treatment option. As a class, T-cell engagers are emerging as an exciting and potentially disruptive therapeutic modality for immunological diseases," said Alistair Henry, Chief Scientific Officer, UCB. He added, "Access to Antengene's cutting-edge T-cell engager platform technology enhances our ambition to lead in immunology. It complements our expertise in monoclonal antibodies and novel biologics, demonstrates our inorganic innovation strategy in action, and brings transformational new capabilities that take UCB into the advancing field of bispecific T-cell engagers."

Antengene's AnTenGager™ platform offers a differentiated T-cell engager approach, where binding of the TCE arm (CD3) is sterically masked in the absence of target antigen binding, providing better tolerability and potent activity.

"We are delighted to partner with UCB, combining our innovative discovery platform and clinical execution capabilities with UCB's deep expertise and experience in immunology to accelerate ATG-201's development efficiently and on a global scale," said Dr. Jay Mei, Founder, Chairman, and CEO of Antengene. "ATG-201, specifically designed for autoimmune diseases, incorporates bivalent CD19 binding, steric hindrance-based masking technology and proprietary CD3 sequence, a strategy designed to enable effective B cell depletion and reduce the risk of cytokine release syndrome (CRS). This collaboration further underscores AnTenGager™ platform's unique capability in developing next generation novel TCEs with broad applicability in different therapeutic areas."

In return of the license rights granted to UCB, Antengene will receive upfront and near-term milestone payments of USD 80 million and would be eligible to receive future success-based development and commercial milestone payments of up to approximately USD 1.1 billion, as well as tiered royalties on future net sales. Further financial details of the agreement were not disclosed.

For further information, contact UCB:

Investor Relations

Antje Witte

T +32.2.559.94.14

email antje.witte@ucb.com

Sahar Yazdian

T +32.2.559.91.37

email <mailto:sahar.yazdian@ucb.com>

Corporate Communications

Laurent Schots

T +32.2.559.92.64

Email laurent.schots@ucb.com

About UCB


UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than

9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that



UCB News

implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.